Pieris Pharmaceuticals Revenue 2011-2026 | PIRS

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Pieris Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	25.9 M	31.4 M	29.3 M	46.3 M	29.1 M	25.3 M	5.83 M	2.93 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
46.3 M	2.93 M	24.5 M

Quarterly Revenue Pieris Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	53 K	-	19.5 M	20.1 M	1.94 M	-	5.37 M	3.7 M	11 M	-	4.06 M	3.28 M	15.6 M	-	2.94 M	11.2 M	13.3 M	-	15.1 M	5.33 M	8.54 M	-	8.34 M	11.7 M	4.15 M	-	3.93 M	1.85 M	1.34 M	-	785 K	1.07 M	1.25 M	-	415 K	160 K	218 K	-	18.7 K	698 K	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
20.1 M	18.7 K	5.9 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
Amphastar Pharmaceuticals AMPH	720 M	$ 21.66	1.14 %	$ 1.01 B	USA
I-Mab IMAB	88 M	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Aptorum Group Limited APM	912 K	$ 0.9	-0.2 %	$ 6.62 M	China
Genfit SA GNFT	70.9 M	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	958 M	$ 22.33	1.66 %	$ 3.7 B	USA
Esperion Therapeutics ESPR	403 M	$ 1.94	1.31 %	$ 403 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
AIkido Pharma AIKI	123 M	-	1.93 %	$ 17.4 M	USA
Heron Therapeutics HRTX	155 M	$ 1.18	-0.84 %	$ 197 M	USA
ImmuCell Corporation ICCC	27.6 M	$ 8.26	-1.07 %	$ 74.6 M	USA
InflaRx N.V. IFRX	29.3 K	$ 1.61	8.78 %	$ 152 M	Germany
AlloVir ALVR	165 K	-	4.14 %	$ 49.1 M	USA
Ampio Pharmaceuticals AMPE	1.16 M	-	-11.43 %	$ 502 K	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Innate Pharma S.A. IPHA	9 M	$ 1.39	0.72 %	$ 235 M	France
Inventiva S.A. IVA	9.2 M	$ 5.11	-0.78 %	$ 138 M	France
Jaguar Health JAGX	11.5 M	$ 0.29	-25.25 %	$ 676 K	USA
Aeterna Zentaris AEZS	7.5 M	-	5.93 %	$ 314 M	Canada
Applied Therapeutics APLT	9.99 M	-	-	$ 8.42 M	USA
Aptinyx APTX	1 M	-	-39.0 %	$ 4.57 M	USA
AgeX Therapeutics AGE	130 K	-	-10.17 %	$ 12.2 K	USA
Aravive ARAV	9.14 M	-	-13.39 %	$ 1.45 M	USA
Aridis Pharmaceuticals ARDS	3.09 M	-	17.91 %	$ 11.1 M	USA
KalVista Pharmaceuticals KALV	49.1 M	$ 19.09	-2.75 %	$ 1.03 B	Britain
BioNTech SE BNTX	482 M	$ 102.36	-2.94 %	$ 27.2 B	Germany
Avenue Therapeutics ATXI	1.4 M	-	-52.27 %	$ 4.45 M	USA
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
Aquestive Therapeutics AQST	44.5 M	$ 4.11	0.61 %	$ 439 M	USA
Arcutis Biotherapeutics ARQT	376 M	$ 23.18	-0.34 %	$ 2.95 B	USA
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
Autolus Therapeutics plc AUTL	75.4 M	$ 1.43	-0.7 %	$ 381 M	Britain
AstraZeneca PLC AZN	58.7 B	-	-	$ 96.9 B	Britain
Ligand Pharmaceuticals Incorporated LGND	167 M	$ 240.72	4.09 %	$ 4.4 B	USA
Eli Lilly and Company LLY	65.2 B	$ 874.81	-1.06 %	$ 785 B	USA
Can-Fite BioPharma Ltd. CANF	853 K	$ 2.9	-0.34 %	$ 4.77 M	Israel
BioDelivery Sciences International BDSI	167 M	-	-4.8 %	$ 255 M	USA